Analysis of how many months and treatment courses it usually takes to cure hepatitis C with Epclusa

Epclusa/Epclusa is an oral antiviral drug composed of sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir) combined direct anti-hepatitis C virus (DAA) therapy. It is indicated for patients with chronic hepatitis C of all genotypes, including those with mild to moderate liver impairment. Because its mechanism of action directly targets viral replication, Jisandai can significantly inhibit viral levels and provide a highly effective solution for curing hepatitis C.

Clinically, the treatment of hepatitis C by Jisanda usually requires 12 weeks (about 3 months) of continuous oral treatment. For some special patients, such as those with liver cirrhosis or those who have failed antiviral treatment in the past, doctors may extend the treatment to 16 to 24 weeks depending on the specific condition to improve the cure rate. In general, the standard treatment course of 12 weeks is suitable for most patients without severe liver function abnormalities, and the length of treatment needs to be evaluated on an individual basis.

While taking the drug, patients will typically undergo blood virology testing, including monitoring of hepatitis C virus (HCV RNA) levels, before and during treatment. Through regular testing, the sensitivity and efficacy of the virus to drugs can be assessed. If HCV RNA remains negative for 12 weeks after the end of the course of treatment, it is considered cured (sustained virological response, SVR12). Follow-up after the course of treatment is also very important to detect recurrence or incomplete treatment in time.

During the period of taking Jisandai, patients should follow the doctor's instructions and take it orally once a day on time, and be careful to avoid missing doses to ensure a complete course of treatment and maximize the efficacy. The oral administration of Jisanda is relatively safe, but liver function and blood routine still need to be monitored regularly, especially in patients with cirrhosis. After completing the course of treatment, regular review to confirm the virus clearance will help to judge the cure effect and prevent recurrence, and provide patients with a complete treatment reference and life management plan.

Reference materials:https://www.drugs.com/